vs
Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and INDEPENDENT BANK CORP (IBCP). Click either name above to swap in a different company.
Cytek Biosciences, Inc. is the larger business by last-quarter revenue ($62.1M vs $58.9M, roughly 1.1× INDEPENDENT BANK CORP). INDEPENDENT BANK CORP runs the higher net margin — 28.6% vs -70.9%, a 99.6% gap on every dollar of revenue. Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs 2.1%).
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
Independent Bank is a bank headquartered in Grand Rapids, Michigan. The bank has 62 branches, all of which are in Michigan.
CTKB vs IBCP — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $62.1M | $58.9M |
| Net Profit | $-44.1M | $16.9M |
| Gross Margin | 52.9% | — |
| Operating Margin | -9.0% | — |
| Net Margin | -70.9% | 28.6% |
| Revenue YoY | 8.1% | — |
| Net Profit YoY | -557.1% | 8.2% |
| EPS (diluted) | — | $0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $58.9M | ||
| Q4 25 | $62.1M | $58.3M | ||
| Q3 25 | $52.3M | $57.3M | ||
| Q2 25 | $45.6M | $55.9M | ||
| Q1 25 | $41.5M | $54.1M | ||
| Q4 24 | $57.5M | $62.0M | ||
| Q3 24 | $51.5M | $51.4M | ||
| Q2 24 | $46.6M | $56.5M |
| Q1 26 | — | $16.9M | ||
| Q4 25 | $-44.1M | $18.6M | ||
| Q3 25 | $-5.5M | $17.5M | ||
| Q2 25 | $-5.6M | $16.9M | ||
| Q1 25 | $-11.4M | $15.6M | ||
| Q4 24 | $9.6M | $18.5M | ||
| Q3 24 | $941.0K | $13.8M | ||
| Q2 24 | $-10.4M | $18.5M |
| Q1 26 | — | — | ||
| Q4 25 | 52.9% | — | ||
| Q3 25 | 52.7% | — | ||
| Q2 25 | 52.3% | — | ||
| Q1 25 | 48.6% | — | ||
| Q4 24 | 58.5% | — | ||
| Q3 24 | 56.3% | — | ||
| Q2 24 | 54.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | -9.0% | 34.8% | ||
| Q3 25 | -17.6% | 37.0% | ||
| Q2 25 | -23.3% | 37.0% | ||
| Q1 25 | -36.1% | 35.3% | ||
| Q4 24 | 5.2% | 36.7% | ||
| Q3 24 | -8.2% | 33.7% | ||
| Q2 24 | -18.3% | 41.0% |
| Q1 26 | — | 28.6% | ||
| Q4 25 | -70.9% | 31.8% | ||
| Q3 25 | -10.5% | 30.5% | ||
| Q2 25 | -12.2% | 30.2% | ||
| Q1 25 | -27.5% | 28.8% | ||
| Q4 24 | 16.8% | 29.8% | ||
| Q3 24 | 1.8% | 26.9% | ||
| Q2 24 | -22.4% | 32.8% |
| Q1 26 | — | $0.81 | ||
| Q4 25 | — | $0.88 | ||
| Q3 25 | — | $0.84 | ||
| Q2 25 | — | $0.81 | ||
| Q1 25 | — | $0.74 | ||
| Q4 24 | — | $0.87 | ||
| Q3 24 | — | $0.65 | ||
| Q2 24 | — | $0.88 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $90.9M | $174.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $341.7M | $510.6M |
| Total Assets | $461.5M | $5.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $174.9M | ||
| Q4 25 | $90.9M | $138.4M | ||
| Q3 25 | $93.3M | $208.7M | ||
| Q2 25 | $75.5M | $146.2M | ||
| Q1 25 | $95.3M | $128.1M | ||
| Q4 24 | $98.7M | $119.9M | ||
| Q3 24 | $162.3M | $121.6M | ||
| Q2 24 | $177.9M | $214.3M |
| Q1 26 | — | $510.6M | ||
| Q4 25 | $341.7M | $503.0M | ||
| Q3 25 | $378.6M | $490.7M | ||
| Q2 25 | $377.6M | $469.3M | ||
| Q1 25 | $379.6M | $467.3M | ||
| Q4 24 | $395.7M | $454.7M | ||
| Q3 24 | $385.5M | $452.4M | ||
| Q2 24 | $389.1M | $430.5M |
| Q1 26 | — | $5.6B | ||
| Q4 25 | $461.5M | $5.5B | ||
| Q3 25 | $494.9M | $5.5B | ||
| Q2 25 | $493.3M | $5.4B | ||
| Q1 25 | $482.6M | $5.3B | ||
| Q4 24 | $499.5M | $5.3B | ||
| Q3 24 | $491.2M | $5.3B | ||
| Q2 24 | $483.7M | $5.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-771.0K | — |
| Free Cash FlowOCF − Capex | $-1.8M | — |
| FCF MarginFCF / Revenue | -2.9% | — |
| Capex IntensityCapex / Revenue | 1.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-8.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-771.0K | $76.7M | ||
| Q3 25 | $-3.9M | $18.2M | ||
| Q2 25 | $108.0K | $19.0M | ||
| Q1 25 | $-125.0K | $31.7M | ||
| Q4 24 | $2.0M | $63.2M | ||
| Q3 24 | $13.2M | $17.2M | ||
| Q2 24 | $6.2M | $8.7M |
| Q1 26 | — | — | ||
| Q4 25 | $-1.8M | $70.2M | ||
| Q3 25 | $-4.6M | $16.5M | ||
| Q2 25 | $-1.5M | $16.7M | ||
| Q1 25 | $-974.0K | $30.6M | ||
| Q4 24 | $1.1M | $55.2M | ||
| Q3 24 | $12.2M | $15.7M | ||
| Q2 24 | $5.2M | $7.0M |
| Q1 26 | — | — | ||
| Q4 25 | -2.9% | 120.3% | ||
| Q3 25 | -8.7% | 28.9% | ||
| Q2 25 | -3.2% | 29.8% | ||
| Q1 25 | -2.3% | 56.5% | ||
| Q4 24 | 1.9% | 89.1% | ||
| Q3 24 | 23.7% | 30.6% | ||
| Q2 24 | 11.0% | 12.3% |
| Q1 26 | — | — | ||
| Q4 25 | 1.6% | 11.1% | ||
| Q3 25 | 1.3% | 2.9% | ||
| Q2 25 | 3.5% | 4.1% | ||
| Q1 25 | 2.0% | 2.1% | ||
| Q4 24 | 1.6% | 12.8% | ||
| Q3 24 | 2.0% | 2.9% | ||
| Q2 24 | 2.3% | 3.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | 4.13× | ||
| Q3 25 | — | 1.04× | ||
| Q2 25 | — | 1.12× | ||
| Q1 25 | — | 2.03× | ||
| Q4 24 | 0.21× | 3.42× | ||
| Q3 24 | 14.05× | 1.25× | ||
| Q2 24 | — | 0.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
IBCP
| Net Interest Income | $46.9M | 80% |
| Noninterest Income | $12.0M | 20% |
